Curis (NASDAQ:CRIS) Posts Quarterly Earnings Results, Beats Estimates By $2.93 EPS

Curis (NASDAQ:CRIS) issued its earnings results on Friday. The biotechnology company reported ($4.02) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($6.95) by $2.93, FiscalAI reports.

Curis Stock Performance

Shares of CRIS opened at $1.80 on Friday. The business’s 50-day moving average is $5.84 and its two-hundred day moving average is $11.74. The company has a market capitalization of $3.76 million, a P/E ratio of -0.08 and a beta of 3.13. Curis has a fifty-two week low of $1.54 and a fifty-two week high of $39.00.

Wall Street Analysts Forecast Growth

A number of research analysts have recently weighed in on CRIS shares. Zacks Research lowered Curis from a “hold” rating to a “strong sell” rating in a report on Tuesday. HC Wainwright reaffirmed a “buy” rating and set a $43.00 target price (up from $17.00) on shares of Curis in a report on Friday, July 24th. Wall Street Zen downgraded Curis to a “strong sell” rating in a report on Saturday, August 8th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Curis in a research report on Friday, July 17th. One research analyst has rated the stock with a Buy rating and two have issued a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Reduce” and an average target price of $43.00.

Hedge Funds Weigh In On Curis

Several institutional investors and hedge funds have recently modified their holdings of CRIS. Jane Street Group LLC boosted its stake in shares of Curis by 71.8% in the fourth quarter. Jane Street Group LLC now owns 25,323 shares of the biotechnology company’s stock worth $25,000 after buying an additional 10,586 shares during the last quarter. XTX Topco Ltd purchased a new position in Curis during the fourth quarter valued at approximately $26,000. Squarepoint Ops LLC raised its position in Curis by 17.9% during the third quarter. Squarepoint Ops LLC now owns 59,140 shares of the biotechnology company’s stock valued at $98,000 after acquiring an additional 8,973 shares in the last quarter. Northwestern Mutual Wealth Management Co. lifted its holdings in Curis by 2,883,237.5% in the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 230,667 shares of the biotechnology company’s stock valued at $228,000 after acquiring an additional 230,659 shares during the period. Finally, Renaissance Technologies LLC lifted its holdings in Curis by 37.3% in the fourth quarter. Renaissance Technologies LLC now owns 240,917 shares of the biotechnology company’s stock valued at $238,000 after acquiring an additional 65,404 shares during the period. Institutional investors and hedge funds own 29.97% of the company’s stock.

Curis Company Profile

Curis, Inc is a biotechnology company focused on the discovery, development and commercialization of targeted small molecule and antibody therapeutics for the treatment of cancer. The company’s research centers on exploiting key signaling pathways and tumor microenvironment interactions to develop compounds with the potential to address unmet medical needs. Curis’ proprietary pipeline includes multiple programs at various stages of clinical and preclinical development, reflecting its emphasis on innovative oncology drug candidates.

Among Curis’ lead assets is CA-4948, an oral inhibitor of interleukin-1 receptor–associated kinase 4 (IRAK4) partnered with Ikena Oncology, which is being evaluated in hematologic malignancies and solid tumors.